Screener
Cogent Biosciences, Inc. COGT Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:21 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205170
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchases of property and equipment | (449) | (547) |
| Purchases of marketable securities | (133,839) | — |
| Maturities and sales of marketable securities | 97,831 | 69,926 |
| Net cash (used in) provided by investing activities | (36,457) | 69,379 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock under ATM, net of issuance costs of $1.4 million and $0.7 million, respectively | 45,712 | 24,250 |
| Proceeds from pre-funded warrant exercises | 6 | — |
| Proceeds from issuance of common stock upon stock option exercises | 5,756 | 136 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Cogent Biosciences, Inc.'s investing cash flow?
- Cogent Biosciences, Inc. (COGT) reported investing cash flow of -$36.46M in Q1 2026.
- How has Cogent Biosciences, Inc.'s investing cash flow changed year-over-year?
- Cogent Biosciences, Inc.'s investing cash flow decreased by 152.5% year-over-year, from $69.38M to -$36.46M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Cogent Biosciences, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude